Demerol vs Morphine for rigors in a patient receving anti-CD20 directed therapy

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org. 

1 post / 0 new
Log in or register to post comments
Tue, 01/14/2025 - 10:41
#1
Zac Pitts
Zac Pitts's picture
Offline
Last seen: 6 days 19 hours ago
Joined: 11/21/2024 - 10:25
Demerol vs Morphine for rigors in a patient receving anti-CD20 directed therapy

What is the policy or clinical practice for the management of patients experiencing rigors/chills as a manifestation of a hypersensitivity reaction to treatment involving anti-CD20 directed treatment (ie. rituximab, obinutuzumab)?

Attach files :
PDF icon 0824_jhop_aug24_lucas.pdf
PDF icon yakubi-et-al-2024-meperidine-compared-to-morphine-for-rigors-associated-with-monoclonal-antibody-related-infusion.pdf
Top